Enterococcus faecium

Agri-Neo's Neo-Pure Pasteurization Technology Receives TERP Validation

Retrieved on: 
Friday, December 2, 2022
Enterococcus faecium, Escherichia coli, Process, Pediococcus acidilactici, Pediococcus, Seed, Food safety, FDA, Pasteurization, NPP, ABC, TERP, Steam, Food, Fumigation, PPO, Onion, Vaccine, Pharmaceutical industry, Listeria, Salmonella

TORONTO, Dec. 2, 2022 /PRNewswire-PRWeb/ -- Agri-Neo is pleased to announce that the Neo-Pure continuous food safety system, and organic pasteurization process at their Toronto Headquarters, have been validated by an ABC-approved Process Authority with agreement by ABC TERP that the Neo-Pure Food Safety System equipment and conditions used in the study demonstrate an ability to meet ABC's criteria of a minimum 4-log destruction of Salmonella bacteria on whole brownskin almonds. Agri-Neo's food safety science studies and third-party test results showed Neo-Pure meets ABC's criteria of a minimum 4-log reduction of pathogens on California almonds.

Key Points: 
  • "We are excited to provide a new pasteurization option to the California almond industry," said Rob Wong, President of Agri-Neo.
  • "Neo-Pure is a proven pasteurization technology for California almonds," said Dr. Fadi Dagher, Biochemistry Director of Agri-Neo.
  • "Neo-Pure is the only TERP-validated pasteurization technology validated using two surrogate bacteria: Pediococcus acidilactici and Enterococcus faecium.
  • The use of surrogate bacteria in food safety is considered a critical component in food safety technology validations.

Adaptive Phage Therapeutics Announces "The AMR RAPID™ Challenge" for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, National, Investigational New Drug, Klebsiella pneumoniae, CEO, Technology, Research, Staphylococcus aureus, RAPID, Therapy, PST, Enterobacter, Challenge, Enterococcus faecium, Infection, ESKAPE, AMR, NIH, Acinetobacter baumannii, Multimedia, MD, United States Department of Defense, FDA, APT, DFO, Congress, Gaps, Bacteria, CDC, Pseudomonas aeruginosa, Patient, Staphylococcus, Pharmaceutical industry, Vaccine, Klebsiella

Through this challenge, APT will pay $1,000 to any individual or institution in the clinical research community that identifies a strain of bacteria (within the CDC's most serious and urgent biological threat categories -- i.e., the "ESKAPE" pathogens*) for which APT cannot demonstrate sensitivity to with its phage bank. Applicants to the AMR RAPID™ Challenge should contact [email protected] for further information, rules, and conditions or visit phagebank.com.

Key Points: 
  • RAPID is APTs acronym for Rapidly Adaptive Phage for Infectious Disease.
  • Applicants to the AMR RAPID Challenge should contact [email protected] for further information, rules, and conditions or visit phagebank.com.
  • APT's phage bank, in combination with APTs Phage Susceptibility Test (PST), closes the loop in antimicrobial development, breaking the failed cycle of repeated antibiotic product introduction followed by obsolescence driven by resistance.
  • Unlike traditional antibiotic development, APT's phage bank approach is designed to adapt to emerging resistance within weeks.

PPG earns prestigious R&D 100 Awards for antimicrobial, antiviral paints

Retrieved on: 
Tuesday, August 30, 2022
General Health, Architecture, Other Construction & Property, Residential Building & Real Estate, Infectious Diseases, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Chemicals, Plastics, COVID-19, Health, Interior Design, Manufacturing, Escherichia coli, COVID-19, Klebsiella pneumoniae, Technology, Research, Staphylococcus aureus, Awareness, Virus, Feline calicivirus, Method, S.A, Coronavirus, Advantage Business Media, Klebsiella aerogenes, Paint, VRE, ISO, Creativity, Severe acute respiratory syndrome coronavirus 2, Opacity, Industry, Pseudomonas aeruginosa, Partnership, Escherichia, Industrial Research Limited, R, Laboratory, Hospital, R&D, Science and technology, School, JIS, Health, ATCC, NYSE, Comex, Vancomycin-resistant Enterococcus, Disinfectant, Enterococcus faecium, Evaluation, MRSA, Nursing, Enterobacter, Corning Inc., Knowledge, Bacteria, Copper, Float glass, Fine chemical, Chemical, Science, Salmonella, PPG, H1N1, Corning

PPG (NYSE:PPG) today announced that two of its industry-leading antimicrobial and antiviral products have been recognized with 2022 R&D 100 Awards in the Mechanical/Materials category COPPER ARMORTM antimicrobial paint by PPG with Corning Guardiant technology and COMEX VINIMEX TOTAL antiviral and antibacterial paint.

Key Points: 
  • PPG (NYSE:PPG) today announced that two of its industry-leading antimicrobial and antiviral products have been recognized with 2022 R&D 100 Awards in the Mechanical/Materials category COPPER ARMORTM antimicrobial paint by PPG with Corning Guardiant technology and COMEX VINIMEX TOTAL antiviral and antibacterial paint.
  • The R&D 100 Awards Committee and R&D World magazine honor the 100 most innovative technologies and services of the past year with the R&D 100 Awards.
  • PPG has earned 34 R&D 100 Awards through the years.
  • Since 1963, the R&D 100 Awards program has identified revolutionary technologies newly introduced to the market and celebrated the top technology products of the year.

LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections

Retrieved on: 
Wednesday, July 27, 2022
University of California, Davis, UPENN, Enterococcus faecium, University, GLOBE, TSX Venture Exchange, Klebsiella, Doctor of Philosophy, Staphylococcus, VMD, Streptococcus, Culture, Intention, Urinary tract infection, LXG, News, SEDAR, Technology, MBA, Company, Escherichia coli, OTCQB, University of Pennsylvania, Professor, DVM, PCR, Kappa, Medical device, Vaccine, Cryptocurrency, Enterococcus, System, Proteus

Each site operated a MiQLab System equipped with a MiQLab Bacterial and AMR Test V2 , which screens samples for 10 common pathogens and 33 markers for antimicrobial resistance factors.

Key Points: 
  • Each site operated a MiQLab System equipped with a MiQLab Bacterial and AMR Test V2 , which screens samples for 10 common pathogens and 33 markers for antimicrobial resistance factors.
  • A total of 105 urine specimens were tested across the two sites, of which, 39 were deemed to be clinically relevant for a urinary tract infection.
  • The MiQLab System successfully detected all Escherichia coli, Staphylococcus, Proteus, Klebsiella, Enterococcus faecium, and Enterococcus faecalis positive samples.
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers.

PPG Receives EPA Registration for COPPER ARMOR Paint Powered by Corning® Guardiant® Technology, Proven to Kill Bacteria and Viruses, Including SARS CoV-2, The Virus That Causes COVID-19

Retrieved on: 
Tuesday, October 5, 2021
Residential Building & Real Estate, Other Retail, Commercial Building & Real Estate, Manufacturing, Construction & Property, Health, Interior Design, Other Manufacturing, Infectious Diseases, Retail, Home Goods, Escherichia coli, Invention, VOC, Partnership, Evaluation, RD&E, Methicillin-resistant Staphylococcus aureus, Engineering, Corning Inc., VRE, Vancomycin-resistant Enterococcus, EPA, Bacteria, Virus, Enterococcus faecium, MRSA, Pseudomonas aeruginosa, United States Environmental Protection Agency, Staphylococcus aureus, Enterobacter, Science, Creativity, Severe acute respiratory syndrome coronavirus 2, Klebsiella pneumoniae, SARS, Klebsiella aerogenes, Work, Copper, NYSE, Staphylococcus, Feline calicivirus, Paint

PPG Copper Armor with Corning Guardiant technology is the first virus killing paint in the U.S., and will provide an extra layer of protection on the walls that surround us where we live, work and learn.

Key Points: 
  • PPG Copper Armor with Corning Guardiant technology is the first virus killing paint in the U.S., and will provide an extra layer of protection on the walls that surround us where we live, work and learn.
  • PPG Copper Armor also provides a mold- and mildew-resistant coating on the dry paint film.
  • Available in eggshell, satin and semi-gloss, PPG Copper Armor can be tinted to more than 600 colors from the PPG paint palette.
  • To learn more about PPG Copper Armor paint and to find a store near you, visit www.ppgpaints.com/copper-armor .

Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

Retrieved on: 
Monday, October 4, 2021
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Patent, Infection, Hand, Vaccine, National, FDA, Mutacin 1140, U.S. Securities and Exchange Commission, Acinetobacter baumannii, Engineering, Enterococcus, Immunization, Food chain, Private Securities Litigation Reform Act, National Research Council, Communication, Enterococcus faecium, Agriculture, Pseudomonas aeruginosa, Florida International University, Staphylococcus aureus, Small business, Enterobacter, COVID-19, Klebsiella pneumoniae, Research, NIGMS, ESKAPE, NIH, Terra, FIU, NYSE, Pharmaceutical industry

The grant provides Oragenics with funding to develop novel lantibiotics for the treatment of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).

Key Points: 
  • The grant provides Oragenics with funding to develop novel lantibiotics for the treatment of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).
  • Telling added, We believe that lantibiotics represent a large untapped pipeline for the development of novel antibiotics.
  • Mutacin 1140 is a lantibiotic discovered by Oragenics, that has provided a basis for the Companys antibiotic research and development and engineering.
  • This funding will support additional molecular modeling efforts and other activities, including in collaboration with FIU, to develop new lantibiotic compounds.

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 9, 2020
Infectious diseases, Pharmaceutical, Health, Bacteria, Lactobacillales, Infectious diseases, RTT, Chemistry, Glycopeptide antibiotics, Antibiotic-resistant bacteria, Vancomycin-resistant Enterococcus, Enterococcus faecium, Vancomycin, Enterococcus, Enterococcus gallinarum

The "Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Infectious diseases, Pharmaceutical, Bacteria, Lactobacillales, Chemistry, Infectious diseases, RTT, Glycopeptide antibiotics, Antibiotic-resistant bacteria, Vancomycin-resistant Enterococcus, Vancomycin, Enterococcus faecium, Enterococcus, Enterococcus gallinarum

The "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vancomycin-Resistant Enterococcus Faecium Infections development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Vancomycin-Resistant Enterococcus Faecium Infections pipeline products by developmental stage, product type, molecule type, and administration route.

NYC Women Doctors Use Tech to Offer Access to Sexual Health Care

Retrieved on: 
Monday, June 18, 2018
Health, RTT, Healthcare quality, Infectious diseases, Health equity, Public health, Urinary tract infection, Candidiasis, Reproductive health, Bacterial vaginosis, Primary care physician, Enterococcus faecium

One of KnowNOW's founders and doctors, Dr. Diana Ramirez mentioned in a recent interview with a Spanish newspaper: "We need more women doctors and we need more health tech solutions from minority providers."

Key Points: 
  • One of KnowNOW's founders and doctors, Dr. Diana Ramirez mentioned in a recent interview with a Spanish newspaper: "We need more women doctors and we need more health tech solutions from minority providers."
  • KnowNOWis offering women's sexual health care in treating simple and quickly treatable conditions like urinary tract infections (UTI), bacterial vaginosis and yeast infections.
  • KnowNOW Health was created by three women primary care physicians asking themselves: "Why is it so difficult for people to get access to medical care?
  • The U.S. has one of the largest income-based health disparities in the world and spends the most on health care of all developed countries.